30
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated with Corifollitropin alfa or rFSH in a GnRH Antagonist Protocol

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Study Question

          What is the threshold for the prediction of moderate to severe or severe ovarian hyperstimulation syndrome (OHSS) based on the number of growing follicles ≥ 11 mm and/or estradiol (E 2) levels?

          Summary Answer

          The optimal threshold of follicles ≥11 mm on the day of hCG to identify those at risk was 19 for both moderate to severe OHSS and for severe OHSS. Estradiol (E 2) levels were less prognostic of OHSS than the number of follicles ≥ 11 mm.

          What Is Known Already

          In comparison to long gonadotropin-releasing hormone (GnRH) agonist protocols, the risk of severe OHSS is reduced by approximately 50% in a GnRH antagonist protocol for ovarian stimulation prior to in vitro fertilisation (IVF), while the two protocols provide equal chances of pregnancy per initiated cycle. Nevertheless, moderate to severe OHSS may still occur in GnRH antagonist protocols if human chorionic gonadotropin (hCG) is administered to trigger final oocyte maturation, especially in high responder patients. Severe OHSS following hCG trigger may occur with an incidence of 1–2% in a relatively young (aged 18 to 36 years) IVF population treated in a GnRH-antagonist protocol.

          Study Design, Size, Duration

          From the Engage, Ensure and Trust trials, in total, 2,433 women who received hCG for oocyte maturation and for whom the number of follicles ≥ 11 mm and the level of E 2 on the day of hCG administration were known were included in the analyses.

          Participants/Materials, Setting, Methods

          The threshold for OHSS prediction of moderate and severe OHSS was assessed in women treated with corifollitropin alfa or daily recombinant follicle stimulation hormone (rFSH) in a gonadotropin-releasing hormone (GnRH)-antagonist protocol. Receiver operating characteristics curve analyses for moderate to severe OHSS and severe OHSS were performed on the combined dataset and the sensitivity and specificity for the optimal threshold of number of follicles ≥ 11 mm, E 2 levels on the day of (hCG), and a combination of both, were determined.

          Main Results and the Role of Chance

          The optimal threshold of follicles ≥ 11 mm on the day of hCG to identify those at risk of moderate to severe OHSS was 19 (sensitivity and specificity 62.3% and 75.6%, respectively) and for severe OHSS was also 19 (sensitivity and specificity 74.3% and 75.3%, respectively). The positive and negative predictive values were 6.9% and 98.6%, respectively, for moderate to severe OHSS, and 4.2% and 99.5% for severe OHSS.

          Limitations, Reasons for Caution

          This was a retrospective analysis of combined data from three trials following ovarian stimulation with two different gonadotropins.

          Wider Implications of the Findings

          For patients with 19 follicles or more ≥11 mm on the day of hCG, measures to prevent the development of OHSS should be considered. Secondary preventive measures include cycle cancellation or coasting, use of a GnRH agonist to trigger final oocyte maturation in place of hCG and a freeze all strategy.

          Trial Registration

          ClinicalTrials.gov NCT00702845

          NCT00696800

          NCT00696878

          Related collections

          Most cited references25

          • Record: found
          • Abstract: found
          • Article: not found

          Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review.

          Ovarian hyperstimulation syndrome (OHSS) is a rare iatrogenic complication of ovarian stimulation occurring during the luteal phase or during early pregnancy. Fortunately, the reported prevalence of the severe form of OHSS is small, ranging from 0.5 to 5%. Nevertheless, as this is an iatrogenic complication of a non-vital treatment with a potentially fatal outcome, the syndrome remains a serious problem for specialists dealing with infertility. The aim of this literature review was to determine whether it is possible to identify patients at risk, and which preventive method should be applied when an exaggerated ovarian response occurs. Data pertaining to the epidemiology and prevention of OHSS in women were searched using Medline, Current Contents and PubMed, and are summarized. Preventive strategies attempt either to limit the dose or concentration of hCG or to find a way to induce luteolysis without inducing a detrimental effect on endometrial and oocyte quality. The following particular preventive strategies were reviewed: cancelling the cycle; coasting; early unilateral ovarian follicular aspiration (EUFA); modifying the methods of ovulation triggering; administration of glucocorticoids, macromolecules and progesterone; cryopreservation of all embryos; and electrocautery or laser vaporization of one or both ovaries.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Incidence and prediction of ovarian hyperstimulation syndrome in women undergoing gonadotropin-releasing hormone antagonist in vitro fertilization cycles.

            To determine the incidence of ovarian hyperstimulation syndrome (OHSS) in a large series of GnRH antagonist-stimulated cycles and to assess the predictive value of E2 and the number of follicles on the day of hCG administration. Prospective cohort study of women undergoing IVF treatment with a GnRH antagonist protocol over a 2-year period. Tertiary university hospital. One thousand eight hundred one patients who underwent 2,524 cycles. Multifollicular ovarian stimulation with recombinant FSH and GnRH antagonist for IVF-ICSI treatment. Incidence of OHSS in GnRH antagonist cycles, predictive value of E2, and number of follicles on the day of hCG for OHSS occurrence. Fifty-three patients were hospitalized because of OHSS (2.1%; 95% confidence interval [CI]:1.6-2.8). Early OHSS presented in 31 patients (1.2%; 95% CI: 0.9-1.8), whereas the late type was a complication in 22 patients (0.9%; 95% CI: 0.5-1.3). Late OHSS cases compared with the early OHSS cases always occurred in a pregnancy cycle (100% vs. 40%); had higher probability of being severe (72.7% vs. 42%), and more often were related to a multiple pregnancy (40% vs. 0). Receiver operating characteristic curve analysis for several E2 concentrations and number of follicles with a diameter of > or =11 mm revealed that the predictive value of the optimal threshold of > or =13 follicles (85.5% sensitivity; 69% specificity) was statistically significantly superior to the optimal threshold of 2,560 ng/L for E2 concentrations (53% sensitivity, 77% specificity) in identifying patients at risk for OHSS. Considering that severe OHSS represents the most clinically significant pattern, the combination of a threshold of > or =18 follicles and/or E2 of > or =5,000 ng/L yields a 83% sensitivity rate with a specificity as high as 84% for the severe OHSS cases. Clinically significant OHSS still remains a limitation of multifollicular ovarian stimulation for IVF even with the use of GnRH antagonist protocols. The number of follicles can discriminate the patients who are at risk for developing OHSS, whereas E2 concentrations are less reliable for the purpose of prediction. There is more than ever an urgent need for alternative final oocyte maturation-triggering medication.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              In vitro maturation as an alternative to standard in vitro fertilization for patients diagnosed with polycystic ovaries: a comparative analysis of fresh, frozen and cumulative cycle outcomes.

              Is in vitro maturation (IVM) as successful as standard in vitro fertilization (IVF) for the treatment of patients with polycystic ovaries (PCO) in terms of fresh, frozen and cumulative pregnancy outcomes?
                Bookmark

                Author and article information

                Contributors
                Role: Editor
                Journal
                PLoS One
                PLoS ONE
                plos
                plosone
                PLoS ONE
                Public Library of Science (San Francisco, CA USA )
                1932-6203
                7 March 2016
                2016
                : 11
                : 3
                : e0149615
                Affiliations
                [1 ]Department of Reproductive Medicine and Gynecological Endocrinology, University Hospital of Schleswig-Holstein, Campus Luebeck, Luebeck, Germany
                [2 ]MSD BV, Oss, The Netherlands
                [3 ]Merck & Co., Inc., Kenilworth, NJ, United States of America
                [4 ]Center for Reproductive Medicine, Universitair Ziekenhuis Brussel, Brussels, Belgium
                [5 ]1st Department of Obstetrics and Gynecology, Papageorgiou Hospital, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece
                Inner Mongolia University, CHINA
                Author notes

                Competing Interests: The authors have the following interests: Financial support for this study was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., the manufacturer of corifollitropin alfa and rFSH. Pierre J. M. Verweij is a former employee of MSD BV, Oss, The Netherlands. Davis Gates, Keith Gordon, and Barbara J. Stegmann are current employees of Merck & Co., Inc., Kenilworth, NJ and may own stock or stock options in the company. Georg Griesinger has received consulting fees from MSD, Ferring, Glycotope, Serono, Finox, Vitrolife, IBSA, and ReprodWissen GmbH; board membership fee from MSD; and speakers’ bureau fees from MSD, Ferring, Serono, Vitrolife, and IBSA. Basil C. Tarlatzis declares unrestricted research and travel grants and honorarium from Merck Serono; unrestricted research and travel grants, honorarium, and speakers bureau fees from MSD; travel grants, honoraria, and advisory board fees from IBSA; and travel grants from Ferring. Paul Devroey has nothing to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.

                Conceived and designed the experiments: PD GG BT. Performed the experiments: PD DG GG BS PV. Analyzed the data: PD DG GG BS PV. Contributed reagents/materials/analysis tools: PD. Wrote the paper: PD DG KG GG BS PV. None.

                Article
                PONE-D-15-29942
                10.1371/journal.pone.0149615
                4780699
                26950065
                0f4a12a0-96e5-47b0-a217-04f767e9e8cb
                © 2016 Griesinger et al

                This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

                History
                : 14 July 2015
                : 3 February 2016
                Page count
                Figures: 4, Tables: 3, Pages: 14
                Funding
                Financial support for this study was provided by Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ. The funder provided financial support in the form of salaries for authors PJMV, DG, KG and BJS, and research materials, but did not have any additional role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. The specific roles of these authors are articulated in the ‘author contributions’ section of the paper.
                Categories
                Research Article
                Biology and Life Sciences
                Cell Biology
                Cellular Types
                Animal Cells
                Germ Cells
                OVA
                Oocytes
                Medicine and health sciences
                Pharmacology
                Pharmacologic-based diagnostics
                GnRH stimulation test
                Medicine and Health Sciences
                Women's Health
                Maternal Health
                Pregnancy
                Medicine and Health Sciences
                Women's Health
                Obstetrics and Gynecology
                Pregnancy
                Biology and Life Sciences
                Biochemistry
                Hormones
                Peptide Hormones
                Follicle-Stimulating Hormone
                Medicine and health sciences
                Clinical medicine
                Clinical trials
                Phase III clinical investigation
                Medicine and health sciences
                Pharmacology
                Drug research and development
                Clinical trials
                Phase III clinical investigation
                Research and analysis methods
                Clinical trials
                Phase III clinical investigation
                Biology and Life Sciences
                Biochemistry
                Hormones
                Lipid Hormones
                Estradiol
                Biology and Life Sciences
                Physiology
                Physiological Parameters
                Body Weight
                Medicine and Health Sciences
                Physiology
                Physiological Parameters
                Body Weight
                Biology and Life Sciences
                Developmental Biology
                Fertilization
                In Vitro Fertilization
                Custom metadata
                All relevant data are within the paper and its Supporting Information files.

                Uncategorized
                Uncategorized

                Comments

                Comment on this article